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diabetes, requiring lifelong exogenous insulin administration and the possibility of numerous sequelae.
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Insulin-dependent diabetes mellitus (IDDM)
is an autoimmune disease characterized by
monocytic and lymphocytic infiltration ofthe
pancreatic islets. This insulitis results in the
gradual destruction ofthe insulin-secreting [B
cells found in the islets and an inability to
maintain blood glucose homeostasis. As a
result, diabetic patients must control blood
glucose levels via exogenous insulin adminis-
tration and are continually at risk for sec-
ondary complications due to fluctuations in
blood glucose. Sequelae such as retinopathy,
kidney failure, neuropathy, and strokes
decrease the diabetic patient's quality oflife
and can eventuallylead to premature death.
Risk for developing IDDM is strongly cor-
related with the expression ofboth major his-
tocompatibility complex (MHC) and a
number ofnon-MHC-related genes. However,
studies ofdisease incidence in identical twins
reveal only a 30-50% concordance rate (1).
This observation has been interpreted to mean
that environmental factors also influence the
disease process. A number ofother findings
also support this notion. For example, individ-
uals who immigrate from a country with low
IDDM incidence to one with high incidence
adopt the higher disease rate ofthe new coun-
try (2). Furthermore, northern countries tend
to have higher frequencies ofIDDM than do
southern countries (3), and the incidence of
IDDM is increasing in countries such as
Sardinia that have relatively stable genetic
backgrounds (4). There also appears to be an
inverse relationship between the development
of IDDM and socioeconomic development
(5). Finally, in animal models ofIDDM, diet
and infection modulate diseasesusceptibility.
In light ofthese observations, investigators
have for years been attempting to identify
environmental factors that contribute to the
development of IDDM in humans. Various
synthetic drugs, diets, and infectious agents
have been implicated in the inhibition and/or
progression of IDDM. Unfortunately,
prospective studies following these factors are
rare and difficult to perform. Also, it is impor-
tant to differentiate between cases ofacute-
onset childhood IDDM and juvenile IDDM.
Both require the administration ofexogenous
insulin, but the mechanisms ofislet destruc-
tion differ significantly between acute-onset
childhood and juvenile IDDM. During acute-
onset IDDM, insulin-secreting [ cells are
destroyed due to direct toxicity ofan agent. [-
Cell destruction occurs quite rapidly and may
or may not involve an autoimmune compo-
nent. In contrast, juvenile-onset IDDM is the
result ofmonocytic- and lymphocytic-medi-
ated [B-cell destruction. This process reflects a
chronic inflammatory response during which
pancreatic islets are first infiltrated with
macrophages, dendritic cells, and T and B
lymphocytes, and [3 cells are progressively
destroyed. Based on observations made in
rodent models of spontaneous IDDM, T
lymphocytes are the primary mediators of [-
cell destruction. Although both types of
IDDM require the administration ofinsulin
for treatment, it is thejuvenile diabetes that is
commonly referred to as type I IDDM.
This review summarizes the vast amount of
work involved in investigating the role ofenvi-
ronmental factors in the development of
IDDM. Potential mechanisms ofinduction of
IDDM by these factors will be reviewed. Both
acute-onset and autoimmune juvenile IDDM
will be covered, and the role ofenvironmental
factors in the development ofeach will be
addressed. Studies performed in animalmodels,
aswell as studies and observations from human
patients, will be included and delineated.
Mechanisms by Which
Environmental Factors May
Influence IDDM
MolecularMimicry
Molecular mimicry is based on two concepts
involving pathogenic antigen and reactive
lymphocytes (6). The first concept is based
on the observation that some pathogen pro-
teins share sequence or structural homology
with self-proteins. For example, the rubella
virus capsid protein shares homology with a
52-kD pancreatic islet antigen (7), and the
coxsackie virus P2-C protein shares homol-
ogy with another pancreatic antigen, glu-
tamic acid decarboxylase (GAD) (8,9). The
second concept is based on the fact that not
all self-reactive T (and B) lymphocytes are
deleted from the repertoire. They may
a) persist because oflow affinity for antigen,
b) exist at a very low frequency, or c) react
with antigens that are normally sequestered
in tissues. In healthy individuals, these
autoreactive T lymphocytes normally exist
and are not pathogenic. It is hypothesized
that upon infection, pathogenic epitopes
that share homology with self-epitopes are
able to activate both pathogen-specific as
well as self-specific T lymphocytes. Although
self-specific T lymphocytes may bind epi-
topes with low affinity, the threshold for
activation may be lowered in the context of
an immune response to the pathogen.
Thus, self-reactive T lymphocytes are acti-
vated and may destroy [B cells expressing the
mimicked antigen.
BystanderActivation
In contrast to molecular mimicry, initial tissue
injury via bystander activation is not directly
antigen specific (10). For example, an infec-
tious agent may induce cell death, resulting in
the release ofself-antigens that have previously
been sequestered. Consequently, these
antigens may activate existing autoreactive
T lymphocytes. In addition, the immune
response elicited by a bacterial or viral infec-
tion typically attracts antigen-presenting cells
and disrupts the cytokine balance [favoring a
predominantly T-helper (Th)1 environment
(see "Immunoregulation")] at the site ofinfec-
tion/inflammation. Therefore, the body's nat-
ural response to pathogenic agents could
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indirectly provide an environment conducive
to the activation ofautoreactive Tlymphocytes
and development ofautoimmune disease (see
"Immunoregulation").
DirectCeliularInjury
Pathogens that infect pancreatic islet cells may
induce IDDM by directly destroying the
insulin-secreting P cells. A critical mass of1
cells may be destroyed after repeated infec-
tions or after asingle severe infection resulting
in clinical IDDM.
Superantig
Superantigens are bacterial or viral products
that activate T lymphocytes expressing spe-
cific 5-chain variable gene(V%) families ofthe
T-cell receptor (TCR) (11). Superantigens
bind the side, not the cleft, ofMHC mole-
cules, and interact with theVp portion ofthe
TCR. Therefore, systemic or tissue-specific
infections may result in superantigen-induced
activation of self-reactive T lymphocytes
found in the periphery.
Imiunoregulation
IDDM is an autoimmune disease in which
pancreatic islet cells are infiltrated and
destroyed by autoreactive CD4+ and CD8+ T
lymphocytes. CD4+ Th lymphocytes (and
CD8+ lymphocytes) are divided into subsets
based on the type ofcytokines secreted and
the type ofimmune response mediated (12).
A number ofstudies have demonstrated that
Thl cells are the primary mediators of1-cell
destruction leading to disease (13). Thl cells
promote inflammatory responses and are
characterized by the production ofinterferon
(IFN)-y and interleukin (IL)-2. In contrast,
Th2 cells confer protection from IDDM in
animal models. Th2 cells promote humoral
immune responses and secrete IL-4 and IL-
10. Whereas IFN-,y and IL-12 promote the
development ofThl cells, IL-4 is necessary
for differentiation ofTh2 cells. Furthermore,
cytokines IFN-y (secreted by Thl cells) and
IL-4 and IL-10 (from Th2 cells) downregu-
late Th2 and Thl effector cell differentiation
and function, respectively. Thus, the Th cell
and cytokine response elicited by an environ-
mental agent may be a factor contributing to
initiation and/orprogression ofIDDM.
Noninfectious Environmental
Factors
DrusChemicalAgents
Animalstdies. Numerous animal models of
drug-induced IDDM exist. Most ofthese
drug regimens mediate acute-onset IDDM,
makingthem especially useful models to study
novel modalities oftreatment for established
disease. Streptozotocin (STZ) is an antibiotic
and chemotherapeutic agent commonly used
to induce IDDM in rodents. A single high
dose ofSTZ initiates P-cell necrosis by 4 hr,
with blood glucose levels peaking (and
remaining high) at 1-2 days (14). The
mechanism ofhigh-dose STZ-induced acute-
onset IDDM appears to be through damage
to the mitochondria ofP cells (15). When
STZ is administered in multiple low doses,
P-cell necrosis begins by day 5 after the final
injection, with blood glucose levels peaking at
1 week or later (after the final injection). This
treatment regime is thought to induce a cell-
mediated immune response, as 5-cell destruc-
tion continues after the STZ has been deared
from the bloodstream (14). Therefore, the
diabetes induced with multiple doses ofSTZ
may more closely resemble the autoimmune
process associatedwithjuvenile-onset IDDM.
A second drug, alloxan, is used to induce
IDDM in animal models. Alloxan is toxic to
,B cells for two reasons (16). First, it rapidly
accumulates in islet cells. Second, upon oxi-
dation, it produces reactive oxygen species
and peroxides that are toxic to t cells.
Consequently, the acute-onset IDDM
induced by alloxan is primarily due to the
accumulation oftoxic byproducts in 1 cells.
Cyclophosphamide is the third drug
commonly used to induce IDDM in animal
models. Two injections of200 mg/kg at 14-
day intervals will induce IDDM in most
mice within 2-3 weeks (17,18). P-Cell
destruction is thought to be due to the elimi-
nation of regulatory T lymphocytes with
concomitant upregulation ofThl responses
(17,18). mRNA expression ofIFN-,y (a Thl
cytokine) and nitric oxide synthase is also
enhanced in islet-infiltrating lymphocytes
when cyclophosphamide is used to accelerate
IDDM induction in the nonobese diabetic
(NOD) mouse model (19).
Human studies. Though there are
numerous reports ofdrug-induced IDDM in
human patients, each case must be examined
to determine its support ofadrugorchemical
agent as a true environmental factor influenc-
ing the disease process. For example, Vacor
[1-(4-nitrophenyl)-3-(3-pyridylmethyl) urea]
is probably the dearest example ofa chemical
that induces IDDM (20). It is a rodenticide
that specifically destroys 1 cells through the
inhibition ofmitochondrial complex I func-
tion (21). Although Vacor clearly is toxic to
P3 cells, it is not considered to be an important
environmental factor contributing to disease
incidence, as it is not normally ingested and
has no clinical benefit to humans. It was, in
fact, removed from the marketafternumerous
accidental poisonings and suicide attempts in
the late 1970s.
IDDM mayalso result from sideeffects of
a drug administered long term, as in cases of
posttransplantation immunosuppression or
the treatment of cancer. In these cases,
patients tend to be extremely ill and are often
administered multiple medications that may
interactwith one another. As aresult, it is dif-
ficult to determine whether the IDDM that
may develop is a result ofa) the underlying
disease state, b) a single medication or a com-
bination ofmedications, and/or c) the med-
ication(s) involved. One such case that has
recently received much attention is the use of
tacrolimus (FK 506 or PrograO, a macrolide
antibiotic often used as part ofan immuno-
suppressive drug regimen. The diabetogenic
effect oftacrolimus depends on numerous
factors, including dose (22,23), patient age
(24-26), and the dose of corticosteroids
administered as part of the regimen (24).
Corticosteroids alone have also been impli-
cated as diabetogenic (because ofalterations
in glucose metabolism), requiring long-term
insulin administration in a small number of
cases (27,28). Further complicating the
situation, some patients regain insulin inde-
pendence when tacrolimus and/or corticos-
teroid doses are reduced or discontinued
(24-26), whereas others do not. This also
appears to be dose dependent. The mecha-
nism by which tacrolimus causes IDDM has
not been fully elucidated, but possibilities
include reduced insulin mRNA synthesis and
inhibition ofinsulin release from pancreatic
P cells, and an increase in peripheral insulin
resistance (29,30). Other chronic medica-
tions that fit this category include chemother-
apeutic agents such as L-asparaginase (31,32)
and IFN-a (33). Although implicated in the
development ofIDDM, no direct evidence
for the involvement ofthese latter drugs or
for the potential mechanism ofaction has
been reported.
Another common occurrence is that a
singledrug is implicated in thedevelopmentof
IDDM but only in a small number ofcases.
For example, pentamidine treatment for
Pneumoystiscariniipneumonitis has led to the
induction ofIDDM following P-cell destruc-
tion (34). Although the involvement ofthe
drug is dear, the low incidence ofIDDM and
the specific patient population involved also
indicate that pentamidine is not a common
cause ofIDDM. Finally, there are occasional
reports ofvarious drugs such as isotretinoin
(35) causing IDDM. It is important to note,
however, that it is not known whether in
these cases the drug had a direct role in the
initiation or progression ofthe disease or if
disease onset were simply coincidental with
drugadministration.
All cases ofdrug- or chemical-induced
IDDM in humans to date appear to be due
to rapid destruction ofpancreatic P cells
and are classified as acute-onset IDDM.
Furthermore, comparison of the structure
and known mechanism of action of these
drugs/chemicals does not reveal any unifying
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features that may in turn correlate with
disease progression.
Food/Diet
Animalstudies. Although the role ofdiet has
been studied in animal models for more than
15 years, data on the influence offood con-
stituents remain incomplete. A recent review
by Akerblom and Knip (36) thoroughly cov-
ers the controversial role ofdiet and food
products in the development of IDDM.
Studies on the effect ofdiet in the BB rat
have shown that plant-based diets are the
most diabetogenic, possibly due to wheat and
soy products (37). The ,B cells ofdiabetic
mice fed such diets exhibit increased expres-
sion ofMHC I molecules and infiltration of
Th cells ofthe Thl phenotype (37). Cow's
milk proteins, N-nitroso compounds, and
gluten are other constituents that may affect
the incidence of IDDM in animal models.
However, some food components such as
casein promote disease in the NOD mouse
model but have no deleterious effect in the
BB rat. As both rodent strains provide excel-
lent models of spontaneous autoimmune
IDDM, such contradictions make determina-
tion of the true role of dietary factors in
disease difficult.
Human studies. Studying the effect of
diet in humans is far more difficult than in
animal models for the obvious reason that the
human diet is usually not controlled for
extended periods oftime, let alone from birth.
Studies ofthe effect ofcow's milk, human
breast milk, N-nitroso compounds, gluten,
bovine serum albumin, fat, and protein on the
development of IDDM are numerous, but
none ofthese factors proven to play a direct
role in thedisease process.
Infectious Environmental
Factors
VirlIandBacterial Infections
Animal studies. The role ofviruses in the
development ofIDDM has been and contin-
ues to be a topic ofgreat interest. The major-
ity of animal studies involving infectious
agents have been based upon induction of
disease following challenge with a given
virus. These studies do not necessarily reflect
the development ofspontaneous IDDM but
nevertheless may provide insight into mecha-
nisms by which viral infection can mediate
IDDM. In addition, viral-induced models
may more closely reflect acute-onset IDDM
and not autoimmune-mediated juvenile-
onset disease. Furthermore, spontaneous viral
and bacterial infections in the NOD mouse
model are known to protect mice from devel-
oping the disease. Therefore, the effect of
infectious agents in diabetic animal models is
still controversial.
Coxsackie-B4 (CVB) (38,39) and
encephalomyocarditis M (40) are two viruses
that have been used to induce IDDM in
rodents. Studies in CD-1 mice challenged
with a diabetogenic strain of CVB have
shown that lymphocytes can destroy acutely
infected islet cells, and macrophages are able
to lyse chronically infected islets. This results
in prolonged hyperglycemia, which reverts to
normoglycemia within 6-12 months in most
cases (38). Destruction of islets by macro-
phages can occur in the absence ofdetectable
viral protein expression (although viral RNA
is detectable), suggesting that the develop-
ment ofIDDM is related to prolonged pres-
ence ofviral RNA in the pancreas. In an
earlier study, it was observed that a) CVB
infection is mouse strain specific, b) a 3-cell
tropic virus is essential, and c) in most cases
IDDM is transient (39). Studies using the
encephalomyocarditis virus to induce IDDM
are also mouse strain specific and result in a
self-limiting disease.
Several groups have developed transgenic
mouse models using genes encoding viral
antigens and subsequent infection with the
corresponding virus in an attempt to induce
IDDM [reviewed in von Herrath et al. (41)].
In these models, expression ofthe viral anti-
gen gene is localized to 1 cells via the rat
insulin promoter. Studies of the immune
response after challenge with virus have pro-
vided information as to the contribution of
T-lymphocyte precursor frequency, thymic
negative selection, local antigen concentra-
tion, and cytokine milieu in the development
of IDDM. All the mice develop IDDM
because ofan autoimmune process mediated
byT lymphocytes, similar to the human juve-
nile onset disease. Despite the usefulness of
these transgenic mouse models, they do not
provide evidence for a direct role for viruses
in the normal development ofIDDM.
The role of bacterial infections in the
development of IDDM has been studied
through observation ofdisease incidence in
NOD mouse colonies (incidence decreases
with bacterial infection) and via administra-
tion of bacterial products in adjuvants or
immunizations. Administration ofcomplete
Freund's adjuvant (CFA) does not prevent
insulitis but does prevent overt IDDM in
NOD mice. Animals protected from disease
have decreased mRNA expression ofThi-type
cytokines (42,43), increasedanti-GAD67 anti-
bodies (GAD is an autoantigen known to be
important in the development ofIDDM), and
Th2 cytokine production (44). It is thought
that Mycobacterium tuberculosisfound in CFA
is responsible for the protective effect ofthe
adjuvant via immune deviation from a pre-
dominandyThI to aTh2 cytokine response.
A second example of protection from
IDDM that implicates a bacterial product
involves the bacille Calmette-Guerin (BCG)
vaccine, which contains Mycobacterium bovis.
BCG protects against IDDM when adminis-
tered within 3 days after cyclophosphamide
treatment (before the onset ofinsulitis in this
model) (45). BCG is also thought to protect
via induction ofimmune deviation; protected
NOD mice exhibit restored anti-GAD67 anti-
body production and increased IL-4:IFN-y
ratios (45).
Human studies. In human patients,
numerous viruses have a role in the develop-
ment of IDDM. The mumps virus, cyto-
megalovirus, Epstein Barr virus, rubella virus,
coxsackie viruses, and retroviruses have all
been found in patients at the time ofdiagno-
sis of IDDM [reviewed in von Herrath et al.
(41)]. However, it is difficult to determine if
a viral infection is coincidental with the onset
of IDDM or has actively contributed to the
disease process that may have been ongoing
for several years prior to any clinical manifes-
tation. Therefore, the precise role viruses play
(ifany) in the development ofIDDM is not
known. For example, viruses may initiate the
destruction of1B cells or promote progression
ofthe diabetogenic response. To gain insight
into these issues, it is necessary to follow a
sufficient number ofgenetically susceptible
individuals to determine whether a correla-
tion between IDDM diagnosis and viral
infections can be established from birth (and
possibly in utero). Currently, this type of
prospective study is extremely difficult to per-
form. Retrospective studies ofviral infections,
although easier to perform, are typically unre-
liable. Many infections may be subclinical and
thus not recorded, and some viruses have the
ability to persist in the body for several years.
Together, these factors make an assessment of
the role of viruses in the development of
IDDM highlyproblematic.
Rubella, coxsackie, and retroviruses have
been studied extensively in recent years. To
date, rubella is the only virus for which con-
clusive evidence exists showing that infection
significantly increases the risk ofdeveloping
IDDM. In a study of 50 patients with con-
genital rubella, 20% of patients developed
IDDM between 18 months and 33 years of
age (46). Studies in which rabbits were
infected in uteroconfirmed histologic changes
in pancreatic 1 cells due to the rubella virus.
It is unknown whether P-cell destruction is
due to direct damage by the virus, or if the
virus induces immunologic changes that indi-
rectly destroy the islet cells. The fact that
patients as young as 18 months develop
IDDM would suggest a direct cytopathic
effect, whereas some patients develop the dis-
ease in a more progressive manner (remaining
insulin-independent until 33 years ofage),
suggesting indirect, possibly autoimmune,
mechanisms ofdamage. Finally, despite an
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established effect on the development of
IDDM, rubella virus nonetheless does not
appear to be a major environmental factor
influencing disease incidence.
CVB is an enterovirus that has been impli-
cated in the development ofIDDM, based on
a number ofobservations [reviewed in Hoyt
et al. (47)]. CVB infects pancreatic P cells in
vitro and in vivo and has been detected in
P cells after acute and fatal cases of IDDM.
Also, IgG and IgM antibodies specific for
CVB and CVB-specific RNA have been
found in the sera ofnewly diagnosed diabet-
ics. Seasonal variation ofCVB infection has in
some regions paralleled incidence of IDDM.
A prospective study found relatively more fre-
quent enteroviral infections during the first
trimester ofpregnancy in mothers whose chil-
dren developed IDDM before 3 years ofage,
with no difference in children developing the
disease between 4 and 6 years ofage. In the
same study, the group ofdiabetic siblings had
a significantly greater number of enterovirus
infections than did nondiabetic siblings (48).
Molecular mimicry, based on homology
between the 2C protein of CVB and GAD,
has been proposed as one mechanism by
which CVB may induce IDDM. Recently,
however, Horwitz et al. (49) used three mouse
models (NOD, B1O.H2g7, BDC2.5) to eluci-
date the mechanism by which CVB may
induce IDDM. No spontaneous immune
response to CVB cross-reactive GAD peptides
was observed in NOD or B1O.H2g7 mice
infected with CVB, which in turn did not
develop IDDM. Both these strains carry the
diabetes-associated MHC class II allele I-Ag7,
which presents GAD peptides to autoreactive
CD4+ T lymphocytes. If CVB induces
IDDM via molecular mimicry, one would
expect enhanced anti-GAD T-cell reactivity
and subsequent development of IDDM in
infected mice. BDC2.5 mice that are trans-
genic for a TCR specific for an unknown pan-
creatic autoantigen (the majority of the
T lymphocytes are specific for this f-cell
autoantigen) exhibit an enhanced onset of
IDDM following infection with CVB. These
results suggest that the CVB infection may
induce IDDM via a bystander mechanism.
Recently, retroviral superantigens have
been implicated in the development of
IDDM. Pancreatic enrichment of the V37
family was observed in two IDDM patients,
suggesting superantigen involvement (50).
The superantigen implicated in those two
cases was encoded by an endogenous retro-
virus related to mouse mammary tumor
viruses (51). The authors propose a two-step
model in which systemic polyclonal activa-
tion ofV17-restricted T cells is triggered by
expression ofthe superantigen in the context
of MHC class II. Subsequently, autoreactive
T cells of the activated subset may initiate
organ-specific destruction of the pancreas.
Though the endogenous retrovirus has been
identified, the mechanism oftissue destruc-
tion and role in disease progression as the ini-
tial trigger, final precipitator, or simply as a
marker ofdisease remains unclear.
Summary
Although environmental factors have been
implicated in the development of IDDM for
years, a unifying influence remains elusive.
Because of the polygenic nature of IDDM,
such unifying factors may not exist. Specific
environmental factors may influence individ-
uals quite differently depending upon the
genotype of that individual. Designing
prospective studies that take into account
genetic background of individuals also
remains an obstacle to obtaining accurate
data on the role of environmental agents. If
these agents do influence the development of
IDDM, it must be determined whether they
function as initiators ofdisease, promote pro-
gression ofan ongoing diabetogenic response,
or play multiple roles in the disease process.
Clearly, direct identification ofenvironmental
factors and their precise role in the disease
process will be extremely useful in prevention
and treatment ofIDDM.
REFERENCES AND NOTES
1. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A,
Eriksson J, Stengard J, Kesaniemi YA. Concordance for type 1
(insulin-dependent) and type 2 (non-insulin-dependent) diabetes
mellitus in a population-based cohort of twins in Finland.
Diabetologia 35:1060-1067 (1992).
2. Patrick SL, Moy CS, Laporte RE. The world of insulin-dependent
diabetes mellitus: what international epidemiologic studies
reveal about the etiology and natural history of IDDM. Diabetes
Metab Rev 5:571-578 (1989).
3. Diabetes Epidemiology Research International Group.
Geographic patterns of childhood insulin-dependent diabetes
mellitus. Diabetes 37:1113-1119 (1988).
4. Songini M, Muntoni S. High incidence of type-I diabetes in
Sardinia [Letter]. Lancet 337:1047 (1991).
5. Singh B, Prange S, Jevnikar AM. Protective and destructive
effects of microbial infection in insulin-dependent diabetes
mellitus. Sem Immunol 10:79-86 (1998).
6. Oldstone MBA. Molecular mimicry and autoimmune disease.
Cell 50:819-820(1987).
7. Karounos DG, Wolinsky JS, Thomas JW. Monoclonal antibody
to rubella virus capsid protein recognizes a P-cell antigen.
J Immunol 150:3080-3085 (1993).
8. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman
DL, Maclaren NK. Cellular immunity to a determinant common
to glutamate decarboxylase and coxsackie virus in insulin-
dependent diabetes. J Clin Invest 94:2125-2129 (1994).
9. Schloot NC, Roep B0, Wegmann DR, Yu L, Wang TB, Eisenbarth
GS. T-cell reactivity to GAD65 peptide sequences, shared with
coxsackie virus protein in recent-onset IDDM, post-onset IDDM
patients and control subjects. Diabetologia 40:332-338 (1997).
10. Benoist C, Mathis D. The pathogen connection. Nature
394:227-228 (1998).
11. Luppi P, Trucco M. Superantigens in insulin-dependent diabetes
mellitus. Springer Semin Immunopathol 17:333-362 (1996).
12. Mosmann TR, Coffman RL. TH1 and TH2 cells: different pat-
terns of lymphokine secretion lead to different functional prop-
erties. Annu Rev Immunol 7:145-173 (1989).
13. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-
dependent diabetes. Science 268: 1185-1190 (1995).
14. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis:
new model of diabetes mellitus. Science 193:41-417 (1976).
15. Welsh N, Paabo 5, Welsh M. Decreased mitochondrial gene
expression in isolated islets of rats injected neonatally with
streptozotocin. Diabetologia 34:626-631 (1991).
16. Malaisse WJ. Alloxan toxicity to the pancreatic P-cell. Biochem
Pharmacol 31(22):3527-3534 (1982).
17. Harada M, Makino S. Promotion of spontaneous diabetes in
non-obese diabetes-prone mice by cyclophosphamide.
Diabetologia 27:604-606 (1984).
18. Yasunami R, Bach J-F. Anti-suppressor effect of cyclophos-
phamide on the development of spontaneous diabetes in NOD
mice. EurJ Immunol 18:481-484(1988).
19. Rothe H, Faust A, Schade U, Kleeman R, Bosse G, Hibino T,
Martin S, Kolb H. Cyclophosphamide treatment of female non-
obese diabetic mice causes enhanced expression of inducible
nitric synthase and interferon-y, but not of interleukin-4.
Diabetologia 37:1154-1158 (1994).
20. Karam JH, Lewitt PA, Toung CW, Nowlaini RE, Frankel BJ,
Fujiya H, Freedman ZR, Grodsky GM. Insulinopenic diabetes
after rodenticide (Vacor) ingestion: a unique model of acquired
diabetes in man. Diabetes 31:40-45 (1980).
21. Esposti MD, Ngo A, Myers MA. Inhibition of mitochondrial com-
plex may account for IDDM induced by intoxication with the
rodenticide Vacor. Diabetes 45:1531-1534 (1996).
22. Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani
L, Griffith BP, Fricker FJ. New-onset diabetes mellitus in pedi-
atric thoracic organ recipients receiving tacrolimus-based
immunosuppression. J Heart Lung Transplant 16:275-282
(1996).
23. Alessiani M, Cillo U, Fung JJ, Irish W, Abu-Elmagd K, Jain A,
Takaya S, Van Thiel S, Starzl TE. Adverse effects of FK 506
overdosage after liver transplantation. Transplant Proc
25:628-634 (1993).
24. Moxey-Mims M, Kay C, Light JA, Kher KK. Increased incidence
of insulin-dependent diabetes mellitus in pediatric renal trans-
plant patients receiving tacrolimus (FK506). Transplantation
65(5):617-619 (1998).
25. Fung J, Alessiani M, Abu-Elmagc K, Todo S, Shapiro R, Tzakis
A, Van Thiel D, Armitage J, Jain A, McCauley J, et al. Adverse
effects associated with the use of FK506. Transplant Proc
23:3105-3108 (1991).
26. Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C,
Tzakis A, Shapiro R, Starzl TE. FK506 associated diabetes melli-
tus in the pediatric transplant population is a rare complication.
Transplant Proc 23:3171-3172 (1991).
27. Perlman K, Ehrlich RM. Steroid diabetes in childhood. Am J Dis
Child 136:64-68 (1982).
28. Owen OE, Cahill GF. Metabolic effects of exogenous glucocorti-
coids in fasted man. J Clin Invest 52:2596-2605 (1973).
29. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF.
Inhibition of glucose-stimulated insulin release from TC3 cells
and rodent islets by an analog of FK 506. Transplantation
55:186-192 (1993).
30. Yale JF, Chamelian M, Courchesne S, Vigeant C. Peripheral
insulin resistance and decreased insulin secretion after
cyclosporine A treatment. Transplant Proc 20(suppl 3):985-988
(1988).
31. Gailani S, Nussbaum A, Onuma T, Freeman A. Diabetes in
patients treated with asparaginase. Clin Pharmacol Ther
12:487-490 (1971).
32. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE.
Toxicity of [-asparaginase in children with advanced leukemia.
Cancer 30:339-347 (1972).
33. Waguri M, Hanafusa T, Itoh N, Imagawa A, Miyagawa J,
Kawata S, Kono N, Kuwajima M, Matsuzawa Y. Occurrence of
IDDM during interferon therapy for chronic viral hepatitis.
Diabetes Res Clin Prac 23:33-36 (1994).
34. Bouchard PH, Sai P, Reach G, Caubarrere I, Ganeval D, Assan R.
Diabetes mellitus following pentamidine-induced hypoglycemia
in humans. Diabetes 31:40-45 (1982).
35. Timperley AC, Withnall RD, Rainford DJ. The development of
insulin-dependent diabetes mellitus in renal transplant patient
receiving oral isotretinoin [Letter]. Nephrol Dialysis Transplant
11:753 (1996).
36. Akerblom HK, Knip M. Putative environmental factors in type
diabetes. Diabetes Metab Rev 14:31-67 (1998).
37. Scott FW. Food-induced type-I diabetes in the BB rat. Diabetes
Metab Rev 12:341-359 (1996).
38. See DM, Tilles JG. Pathogenesis of virus-induced diabetes in
mice. J Infect Dis 171:1131-1138 (1995).
39. Yoon J-W, Onodera T, Notkins AL. Virus-induced diabetes
mellitus-,B cell damage and insulin-dependent hyperglycemia in
mice infected with coxsackie virus B4. J Exp Med 148:1068-1080
(1978).
40. Notkins AL. Virus-induced diabetes mellitus-brief review.
Arch Virol 54:1-17 (1977).
780 Environmental Health Perspectives * Vol 107, Supplement 5 * October 1999FACTORS THAT INFLUENCE IDDM
41. von Herrath MG, HoIz A, Homann D, Oldstone MBA. Role of
viruses in type diabetes. Sem Immunol 10:87-100(1998).
42. Shehadeh NN, La Rosa F, Lafferfty KJ. Altered cytokine activity
in adjuvant inhibition of autoimmune diabetes. J Autoimmunity
6:291-296(1991).
43. Rabinovitch A. Suarez-Pinzon WL, Sorensen 0, Bleackley RC,
Power RF. IFN-'y gene expression in pancreatic islet-infiltrating
mononuclear cells correlates with autoimmune diabetes in
nonobese diabetic mice. J Immunol 154:4874-4882(1995).
44. Qin H-Y, Elliot J-F, Rajotte RV, Singh B. Endogenous immune
responses toglutamic acid decarboxylase (GAD67) in NOD mice
are modulated by adjuvant immunotherapy [Abstract].
Autoimmunity24(suppl 1):A133 (1996).
45. Din H-Y, Singh B. BCG vaccination prevents insulin-dependent
diabetes mellitus (IDDM) in NOD mice afterdisease acceleration
with cyclophosphamide. JAutoimmunity 10:271-278(1997).
46. Menser MA, ForrestJM, Bransby RD. Rubella infection and dia-
betes mellitus. Lancet 1:57-60(1978).
47. Hyoty H, Hiltunen M., Lonnrot M. Enterovirus infections and
insulin-dependent diabetes mellitus-evidence for causality.
Clin DiagVirol 9:77-84(1998).
48. Hyoty H, Hiltunen M, Knip M, Laakkonen M, Vahasalo P,
Karjalainen J, Koskela P, Roivainen M, Leinikki P, Hovi T et al.
Childhood Diabetes in Finland (DiMe) Study Group. A prospec-
tive study ofthe role of coxsackie B and other enterovirus infec-
tions inthepathogenesis of IDDM. Diabetes44:652-657 (1995).
49. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J,
Sarvetnick N. Diabetes induced by coxsackie virus: initiation by
bystander damage and not molecular mimicry. Nat Med
4(7):781-785 (1998).
50. Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R,
Ricordi C, Rodriquez-Rilo H, Finegold D, Trucco M. Evidence for
superantigen involvement in insulin-dependent diabetes melli-
tus aetiology. Nature 371:351-355(1994).
51. Conrad B,Weissmahr RN, Boni J,Arcari R, Schupbach J, Mach B.
A human endogenous retroviral superantigen as candidate
autoimmune gene intype diabetes. Cell 90:303-313 (1997).
Environmental Health Perspectives * Vol 107, Supplement 5 * October 1999 781